Navigation Links
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
Date:10/25/2011

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.

The top priority of Conatus is patient safety, and the Company has made the decision to halt this study.  Conatus is conducting a thorough review of the available data to assess any future development of the compound.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
2. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
5. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
7. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
8. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... Florida State University research team has led to a ... white light, and convert photon energy directly to mechanical ... , Biwu Ma, associate professor in the Department of ... Engineering, created the molecule in a lab about a ... creation has many other unique capabilities. , For example, ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... and OXFORD, England, February 28, Evotec AG (Frankfurt ... first Phase II study for EVT 302 in ... monoamine oxidase,B (MAO-B)., This double-blind, three-way cross-over ... 302 on craving and withdrawal symptoms,after short-term deprivation ...
... New England Journal of Medicine, led by researchers at ... University of Massachusetts Medical School (UMMS), indicates a declining ... the first demonstration of a link between two independent ... has offered universal newborn screening to detect cystic fibrosis ...
... Repurchase Program -, LIONVILLE, Pa., Feb. 27 West ... Board of Directors,approved a second quarter 2008 cash dividend of ... 2008 to shareholders of record on April 23,2008., The ... common stock at an average price of $40.23 per share ...
Cached Biology Technology:Evotec Starts Phase II in Smoking Cessation with EVT 302 2Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:8/28/2014)... Athens, Ga. The support of peer groups ... effective breastfeeding programs, according to recent University of ... mothers in the Athens-Clarke County area determined that ... the outcomes of mothers of infants. , "Mothers ... be successful at breastfeeding," said study co-author Alex ...
(Date:8/28/2014)... , Aug. 28, 2014  Privacy Advocate and ... Jennifer Lynch , joins the lineup of biometric ... second annual Biometrics UnPlugged Executive Summit in ... Previously announced speakers include Steven Rahman, Director, Technology ... Public Sector at Experian. The theme of this year,s ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine,s Conference on Integrative Physiology of ... These awards are meant to promote the ... underrepresented groups into the mainstream of the basic ... young scientists at the American College of Sports ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... -- An internationally-recognized gynecologic oncologist at St. Joseph,s Hospital and ... from a long-awaited global study of ovarian cancer should be ... month, the study reported that women who received early chemotherapy ... than those whose treatment is delayed. London-based, The ...
... - Dr. Jane Lubchenco, U.S. Under Secretary of Commerce for ... keynote speaker for a major academic conference on the ... the University of South Florida, the Florida Institute of Oceanography, ... Academic Task Force. Lubchenco, who played a leading role ...
... and streams supply the lifeblood of ecosystems across the globe, ... as a wide array of life forms in rivers and ... fish humans eat. But humans and nature itself are making ... to support fish species, according to new research by a ...
Cached Biology News:Gynecologist disputes findings 2Lubchenco to headline Gulf of Mexico Oil Spill Conference speaker lineup 2A river ran through it 2A river ran through it 3A river ran through it 4
A univariate (peak height or area) quantitative multi-component analysis package....
... The new, upgraded micro 10 represents a ... brings many of the benefits of large ... the small benchtop dispenser. Dispensing accurate volumes ... the micro 10 has unique advantages not ...
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
Biology Products: